You are adding an alert for:
Efficacy and safety of ranibizumab 0.5 mg treat and extend versus monthly regimen in patients with neovascular age-related macular degeneration: 12-month results from the TREND study.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: